NCT00144508View on ClinicalTrials.gov

Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)

PHASE3CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

May 31, 2004

Study Completion Date

February 28, 2006

Conditions
Rheumatoid Arthritis
Interventions
DRUG

MRA (Tocilizumab)

8mg /kg /4week for 52 weeks

OTHER

current treatment

continue current treatment

Sponsors
All Listed Sponsors
lead

Chugai Pharmaceutical

INDUSTRY

NCT00144508 - Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA) | Biotech Hunter | Biotech Hunter